Consensus Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX 11:46:44 05/11/2026 pm IST			5-day change	1st Jan Change
171.13 ^USD	-1.92%		+2.98%	+38.95%

11:18pm	Maxim Adjusts Price Target on Gilead Sciences to $200 From $165	MT
10:58pm	Gilead Sciences' Phase 3 Livdelzi Study Shows Improvements in Adults With Primary Biliary Cholangitis	MT

Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

b697f55e3acd149aca875b.FZu7KoFp4AhymLlTucYhltUMbrOOn9cVMQR79t2ydOg.WfbBaO4xtUMgoI5llLIQ2YxLVvbi7-9EUDEZmYv3DqNPyf9_1zGRbQLQ1g~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

11:18pm	Maxim Adjusts Price Target on Gilead Sciences to $200 From $165	MT
04/11	DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167	MT
30/10	Gilead's HIV Franchise Supports Growth Outlook, RBC Says	MT
30/10	UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy Rating	MT
30/10	Needham Adjusts Price Target on Gilead Sciences to $200 From $170	MT
30/10	Leerink Partners Adjusts Price Target on Gilead Sciences to $145 From $129	MT
30/10	RBC Raises Price Target on Gilead Sciences to $131 From $126, Keeps Sector Perform Rating	MT
29/10	Not All AI Billions Are Equal
21/10	Gilead's Biktarvy Pricing Impact Likely Manageable, RBC Says	MT
15/10	Goldman Sachs Adjusts Price Target on Gilead Sciences to $142 From $135	MT
12/10	Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says	MT
12/10	BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating	MT
08/10	RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating	MT
07/10	Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165	MT
07/10	JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160	MT
02/10	Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says	MT
10/09	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT
05/08	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
05/08	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
05/08	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
05/08	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
04/08	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
28/07	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
23/07	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
21/07	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GILEAD SCIENCES, INC.					-1.13%
	ELI LILLY AND COMPANY					+1.7%
	JOHNSON & JOHNSON					+1.12%
	ABBVIE INC.					+3.93%
	ROCHE HOLDING AG					-0.35%
	MERCK & CO., INC.					+7.43%
	NOVARTIS AG					-6.46%
	ASTRAZENECA PLC					+13.37%
	AMGEN INC.					-15.5%
	NOVO NORDISK A/S					+4.22%
	Average					+0.83%
	Weighted average by Cap.					+1.34%